200
Participants
Start Date
July 5, 2017
Primary Completion Date
October 31, 2025
Study Completion Date
October 31, 2025
Alectinib
Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
Crizotinib
Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
Centre Francois Baclesse, Caen
Centre Georges François Leclerc, Dijon
Hospital Universitario La Paz, Madrid
CHU de Toulouse - Hôpital Larrey, Toulouse
Irccs Centro Di Riferimento Oncologico (CRO), Aviano
Groupe Hospitalier Sud - Hôpital Haut Lévêque, Pessac
Istanbul Uni Capa Medical Faculty, Istanbul
Hopital Pontchaillou - CHU de Rennes, Rennes
Ege University Medical Faculty, Izmir
Azienda Ospedaliero-Universitaria Careggi, Florence
Hopital Robert Schuman, Vantoux
Centre Oscar Lambret, Lille
Centre Leon Berard, Lyon
Chao Family Comprehensive Cancer Center, Orange
"FSBSI Russian Oncological Scientific Center n.a. N.N. Blokhin", Moscow
University ?linic of headaches, Moscow
City Clinical Oncology Hospital, Moscow
Massachusetts General Hospital Cancer Center, Boston
Queen Mary Hospital, Hong Kong
Queen Elizabeth Hospital Department of Clinical Oncology, Kowloon
Azienda Ospedaliera San Camillo Forlanini - Unità Operativa Complessa di Pneumologia Oncologica 1, Rome
Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia, Perugia
Uniwersyteckie Centrum Kliniczne, Gda?sk
Seoul National University Hospital, Seoul
Samsung Medical Center, Seoul
Hospital del Mar, Barcelona
Hospital Universitari Dexeus - Grupo Quironsalud, Barcelona
Adana Ac?badem Hospital Oncology Department, Adana
Hacettepe Uni Medical Faculty Hospital, S?hhiye, Ankara
Hoffmann-La Roche
INDUSTRY